166 related articles for article (PubMed ID: 35634752)
21. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
[TBL] [Abstract][Full Text] [Related]
22. Febuxostat Use and Safety in Patients With Hyperuricemia.
Kawada T
J Rheumatol; 2022 Oct; 49(10):1180. PubMed ID: 35705244
[No Abstract] [Full Text] [Related]
23. Successful Desensitization to Febuxostat in a Patient With Hypersensitivity to Allopurinol and Febuxostat and Review of the Literature.
Koenig D; Royer C; Azar A
J Clin Rheumatol; 2021 Dec; 27(8S):S432-S433. PubMed ID: 31977653
[No Abstract] [Full Text] [Related]
24. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
25. Confounding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'.
Hsu PK; Lee YH; Wei JCC
Ann Rheum Dis; 2022 Jul; 81(7):e122. PubMed ID: 32561600
[No Abstract] [Full Text] [Related]
26. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014-2017.
Weisshaar S; Litschauer B; Reichardt B; Gruber F; Leitner S; Sibinovic S; Kossmeier M; Wolzt M
Rheumatol Int; 2022 Sep; 42(9):1597-1603. PubMed ID: 35589988
[TBL] [Abstract][Full Text] [Related]
28. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
29. Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu
Singh JA
Ann Rheum Dis; 2022 Jul; 81(7):e123. PubMed ID: 32561601
[No Abstract] [Full Text] [Related]
30. Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.
Tong Q; Du Y; Cui R; Chen M; Wang SI; Wei JC; Dai SM
Drugs; 2022 Dec; 82(18):1717-1726. PubMed ID: 36479686
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Safety of Febuxostat in Patients With Gout or Hyperuricemia: A Systematic Review of Randomized Controlled Trials.
Ghossan R; Aitisha Tabesh O; Fayad F; Richette P; Bardin T
J Clin Rheumatol; 2024 Mar; 30(2):e46-e53. PubMed ID: 38115182
[TBL] [Abstract][Full Text] [Related]
32. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
33. Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.
Jansen TLTA; Janssen M
Clin Rheumatol; 2019 Jan; 38(1):263-265. PubMed ID: 30542798
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular safety associated with febuxostat versus allopurinol among patients with gout: Update with accumulated use of febuxostat.
Shin A; Choi SR; Han M; Ha YJ; Lee YJ; Lee EB; Kang EH
Semin Arthritis Rheum; 2022 Oct; 56():152080. PubMed ID: 35973263
[TBL] [Abstract][Full Text] [Related]
35. Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
Castrejon I; Toledano E; Rosario MP; Loza E; Pérez-Ruiz F; Carmona L
Rheumatol Int; 2015 Jul; 35(7):1127-37. PubMed ID: 25519877
[TBL] [Abstract][Full Text] [Related]
36. Febuxostat for treating chronic gout.
Tayar JH; Lopez-Olivo MA; Suarez-Almazor ME
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008653. PubMed ID: 23152264
[TBL] [Abstract][Full Text] [Related]
37. The Association of Febuxostat Compared With Allopurinol on Blood Pressure and Major Adverse Cardiac Events Among Adult Patients With Hyperuricemia: A Meta-analysis.
Barrientos-Regala M; Macabeo RA; Ramirez-Ragasa R; Pestaño NS; Punzalan FER; Tumanan-Mendoza B; Castillo RR
J Cardiovasc Pharmacol; 2020 Oct; 76(4):461-471. PubMed ID: 32675751
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy.
Gupta MK; Singh JA
Drugs; 2019 Apr; 79(5):531-541. PubMed ID: 30868398
[TBL] [Abstract][Full Text] [Related]
39. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
